Biotech Values

[oldberkeley]

I don’t think Hamburg’s resignation affects biotech investors to a material degree.

Only if we wind up with someone worse, which could happen since she was excellent.

Folks on quite a few iHub boards—AMRN comes to mind—have demonized Dr. Hamburg and the FDA in general instead of taking a hard look at their actual investment, the company and the drug.

It’s hard not to throw that stone when decisions don’t go your way and you lose money (I’ve been guilty of that myself) but in general I think she’s done a good job.